CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 64 enrolled
Drug / intervention
CUTAQUIGdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03939533
NCT03939533Phase 3Completed
CompareCT.gov

Clinical Phase 3 Study to Monitor the Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin (CUTAQUIG®) Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

Octapharma·interventional·Posted May 6, 2019·Updated Nov 7, 2023

In Brief

A Phase 3 clinical trial evaluating CUTAQUIG for Primary Immune Deficiency Disorder. Completed, enrolled 64 participants across 18 sites.

Detailed Summary

CLINICAL PHASE 3 STUDY TO MONITOR THE SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (CUTAQUIG®) ADMINISTERED AT MODIFIED DOSING REGIMENS IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Immune Deficiency Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 6, 2019
Enrollment StartOct 17, 2019
Primary CompletionJan 3, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.2 years ago

Interventions

CUTAQUIGdrug

Human normal immunoglobulin